PREVENT Tool Revolutionizes Global Heart Disease Risk Prediction

A new cardiovascular risk assessment tool, called PREVENT, has been validated in a major global study. Published in Nature Medicine, the research confirms its superior accuracy over older models. The findings suggest it could transform how doctors predict and manage heart disease risk worldwide. The PREVENT tool was originally designed for the US population but has now proven effective across diverse regions. Researchers validated its performance using data from over 6.4 million people in North America, Europe, and Asia. This broad testing highlights its reliability in different healthcare settings.

Unlike older models such as the Pooled Cohort Equation (PCE), PREVENT delivers sharper predictions, especially for those at low-to-moderate risk. It assesses both 10- and 30-year risks of heart attack, stroke, and heart failure. By including renal function markers like albuminuria, its accuracy improves further. Clinicians can use the tool to tailor treatments, deciding when to prescribe cholesterol-lowering drugs, blood pressure medications, or lifestyle advice. Its adoption could lead to more consistent international guidelines, standardising how cardiovascular risk is managed globally.

The validation of PREVENT represents a major step forward in preventive cardiology. Its ability to refine risk assessments and guide personalised care may improve patient outcomes worldwide. The study’s publication in Nature Medicine underscores its potential impact on clinical practice.